uniQure N.V. (QURE): Shareholders' Equity
$198.90M
As of 2025-12-31
$149.34M
As of 2026-03-31
-25.2%
3-year compound annual growth
-4.0%
5-year compound annual growth
+4.5%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $198.90M | n/m | 2026-03-02, Balance as of period end |
| 2024-12-31 | -$6.75M | n/m | 2026-03-02, Balance as of period end |
| 2023-12-31 | $207.67M | -56.4% | 2026-03-02, Balance as of period end |
| 2022-12-31 | $476.01M | -20.1% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $595.78M | +144.3% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $243.91M | -24.5% | 2023-02-27, Balance as of period end |
| 2019-12-31 | $323.06M | +79.9% | 2022-02-25, Balance as of period end |
| 2018-12-31 | $179.61M | +101.0% | 2021-03-01, Balance as of period end |
| 2017-12-31 | $89.36M | +40.4% | 2020-03-02, Balance as of period end |
| 2016-12-31 | $63.63M | -50.3% | 2019-02-28, Balance as of period end |
| 2015-12-31 | $127.93M | +200.1% | 2018-03-14, Balance as of period end |
| 2014-12-31 | $42.63M | n/a | 2017-03-15, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| uniQure N.V. (QURE) | 2025-12-31 | $198.90M | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $15.35M | +128.3% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $76.58M | -21.4% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $53.41M | -55.8% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $1.47M | -18.2% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $22.81M | -20.9% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $245.15M | +75.7% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $205.57M | n/m |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | -$74.34M | n/m |
Compare QURE, IRD, ABUS, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗